Current issues in malignant pleural mesothelioma evaluation and management

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Research

Background:

• Malignant pleural mesothelioma (MPM) is an uncommon cancer linked to asbestos exposure, with increasing global incidence.
• Patients often present with advanced disease, comorbidities, and poor prognosis, complicating treatment.
• Current treatments include surgery for select patients and chemotherapy for unresectable disease, but resistance is common.

Purpose of the Study:

• To review the current challenges and emerging therapeutic strategies for malignant pleural mesothelioma.
• To highlight the importance of patient selection for surgical resection.
• To discuss the role of chemotherapy and the potential of novel agents in MPM treatment.

Main Methods:

• Review of existing literature on MPM diagnosis, treatment, and prognosis.
• Analysis of current surgical approaches like extrapleural pneumonectomy (EPP) and extended pleurectomy/decortication (e-P/D).
• Discussion of chemotherapy regimens and emerging targeted therapies based on translational research.

Main Results:

• Surgical resection in selected patients can improve survival as part of a multimodal approach.
• Pemetrexed and platinum chemotherapy is standard for unresectable MPM, improving survival and quality of life.
• MPM often develops resistance to initial therapies, necessitating further treatment options.

Conclusions:

• Optimizing patient selection for surgery is crucial due to associated morbidity.
• Novel therapeutic agents derived from translational research show promise for a new era in MPM treatment.
• Ongoing research aims to overcome treatment resistance and improve outcomes for MPM patients.